Boehringer Ingelheim merges AMAL and ViraTherapeutics cancer units, Dantari sells assets to Adanate, Madrona raises $770M, and Abdera adds JJDC and Foresite as investors.

A new report from Novotech reveals the OV market is expanding at pace, with a compounding annual growth rate of 14.2% between 2019 and 2024. More than 95% of ongoing trials involving oncolytic viruses ...

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to ...

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will participate in the ...

Cancer treatment using common cold virus offers hope for patients Some of the most common cancers in the US could soon be ...

As our knowledge of science and the human body expands, so too do doctors have more tools at hand when treating cancer. One ...

LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for ...

Scientists have disguised tumours to ‘look’ similar to pig organs ― tricking the immune system into attacking the cancerous ...

Evan Seigerman, an analyst from BMO Capital, has initiated a new Buy rating on Replimune Group (REPL).Stay Ahead of the Market:Discover ...

In a recent study, researchers from Uppsala University have shown that the Semliki Forest virus enters the central nervous ...

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic ...